30 Years Later, A MacArthur 'Genius' Reflects
By Kat Chow,
WGBH News
| 09. 26. 2013
[Discusses the work of CGS's Osagie Obasogie]
On Wednesday, the MacArthur Foundation announced its newest class of fellows — "geniuses" who have made remarkable contributions to their fields. We wanted to know what happens to a "genius" after the fellowship is over, so we spoke with Ramón Gutiérrez, a Preston and Sterling Morton Distinguished Service Professor in U.S. history at the University of Chicago, and one of the MacArthur fellows in 1983.
He told us about research in Chicano studies that fascinates him, what questions he asks in his own research, and what holes he sees in ethnic studies. During his time as a fellow, Gutiérrez wrote When Jesus Came the Corn Mothers Went Away, a monograph on marriage, sexuality and power in New Mexico.
Interview with Ramón Gutiérrez
How'd you react when you heard the news when you were a MacArthur fellow?
It was the second group of MacArthur fellows. I had read something about it, but I didn't know much about it. You know, when someone calls you up — I think the amount of money I had was something like $352,000 by 1982...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...